Finance News World

Myopia Overview

Myopia (also known as nearsightedness) refers to a spectrum of ocular disorders in which the far point of the eye is closer to the retina than infinity. It is becoming a worldwide epidemic and imposes a tremendous public health burden. Consequently, the global initiative for eliminating avoidable blindness has grouped refractive error as one of five leading causes of blindness and visual impairment in the world.

“Myopia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myopia Market.

The Myopia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myopia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myopia treatment therapies with a considerable amount of success over the years. Myopia Key players such as – Nevakar, Bausch & Lomb Incorporated, Sydnexis, Hoya Vision,, Coopervision, Inc., Kubota Vision Inc., Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., Alcon Inc., HOYA VISION CARE COMPANY, Synergeyes, Sightglass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark’ennovy, Euclid Systems Corporation, and others, are developing therapies for the Myopia treatment 

• Myopia Emerging therapies such as – NVK-002, Atropine 0.1% Ophthalmic Solution, SYD-101, MiyoSmart, and others are expected to have a significant impact on the Myopia market in the coming years.   

Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Myopia Pipeline Therapeutics Assessment

• Myopia Assessment by Product Type
• Myopia By Stage and Product Type
• Myopia Assessment by Route of Administration
• Myopia By Stage and Route of Administration
• Myopia Assessment by Molecule Type
• Myopia by Stage and Molecule Type

DelveInsight’s Myopia Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Myopia Therapeutics Market include:

Key companies developing therapies for Myopia treatment are – ALCON Inc., Bausch Health Companies Inc., Johnson & Johnson Vision, Topcon Corporation, Zeimer Ophthalmic Systems AG, and others

Emerging Myopia Drugs Under Different Phases of Clinical Development Include:

• NVK-002: Nevakar
• Atropine 0.1% Ophthalmic Solution: Bausch & Lomb Incorporated
• SYD-101: Sydnexis
• MiyoSmart: Hoya Vision

Get a Free Sample PDF Report to know more about Myopia Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Myopia Pipeline Analysis:

The Myopia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.
• Myopia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Myopia product details are provided in the report. Download the Myopia pipeline report to learn more about the emerging Myopia therapies

Myopia Pipeline Market Drivers

• Growing cases of vision loss
• Technological advancements in the type or range of treatments available on the market such as LASIK surgery

Myopia Pipeline Market Barriers

• Stringent government approvals
• Excessive use of digital channels

Scope of Myopia Pipeline Drug Insight    

• Coverage: Global
• Key Myopia Companies: Nevakar, Bausch & Lomb Incorporated, Sydnexis, Hoya Vision,, Coopervision, Inc., Kubota Vision Inc., Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., Alcon Inc., HOYA VISION CARE COMPANY, Synergeyes, Sightglass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark’ennovy, Euclid Systems Corporation, and others
• Key Myopia Therapies: NVK-002, Atropine 0.1% Ophthalmic Solution, SYD-101, MiyoSmart, and others
• Myopia Therapeutic Assessment: Myopia current marketed and Myopia emerging therapies
• Myopia Market Dynamics: Myopia market drivers and Myopia market barriers 

Request for Sample PDF Report for Myopia Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Myopia drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services